Method(s): MALDI-TOF MS.
What is measured: Glycated hemoglobin (HbA1c).

What is measured on the same platform, click here.
Platform G: HbA1c is measured in whole blood and not simultaneously with the serum/plasma biomarkers.

What is HbA1c?

It is formed by non-enzymatically attachment of glucose to different amino groups of both 2 alpha and 2 beta chains of normal adult hemoglobin A (HbA). The relative amount of glucose bond to the N-terminal of the beta chain is measured as HbA1c. HbA1c is used to monitor long-term glycaemic control and treatment of diabetes.

Performance of the assay

Lower limit of detection (LOD): na.
Within-day CV, 5 %; between-day CV, na.
No interferences from bilirubin, triglyceride, labile A 1c, and carbamylated hemoglobin (1).


Assessment of long-term glycemic control in diabetics.

Specimen, collection and processing

Matrix: Whole blood.
Volume: Minimum volume is 20 µL, but 100 µL is optimal and allows reanalysis.
Preparation and stability: The blood sample must be put on ice, and frozen. HbA1c is stable for one week at 4-8C. At -70 °C, HbA1c is stable for many years and slightly increases if stored for more than one decade.

Transportation; for general instruction on transportation, click here.

Frozen, on dry ice.

Reference values, interpretation

Reference values: 4-6%.
In diabetes patients values can range from 6.5 up to 14%.
Intraclass correlation coefficient (ICC): na.


1. Xu, A., Wang, Y., Li, J., Liu, G., Li, X., Chen, W. et al. (2019). Evaluation of MALDI-TOF MS for the measurement of glycated hemoglobin. Clin Chim Acta, 498, 154-160.